Comparative study of a moisturizer and topical tarcrolimus for treating atopic dermatitis

A side-by side comparative study of a moisturizer and topical tacrolimus for treating mild to moderate atopic dermatitis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0007962

Enrollment

Registered

2022-12-05

Start date

2021-01-14

Completion date

Unknown

Last updated

2023-01-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug, Others(moisturizer) : The test cream used in this study is BARRIEDERM CREAM MD® (Cell Fusion C, Seoul, Republic of Korea), which contains various components, including a lipid mixture (Neo-CMS®

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Eligible patients are 20-70 years old with a diagnosis of clinically stable AD. Diagnosis of AD is performed by a board-certified dermatologist using Hanifin and Rajka’s criteria. Patients are required to have Eczema Area and Severity Index (EASI) scores of = 7 (mild) or 7-21 (moderate).

Exclusion criteria

Exclusion criteria: Active states of other dermatitis or eczematous conditions, skin infection requiring oral or topical antimicrobial therapy, or previous treatment with oral or topical corticosteroids or immunosuppressants within the past four weeks.

Design outcomes

Primary

Measure	Time frame
Investigator’s Global Assessment ;modified Eczema Area and Severity Index (mEASI)	—

Secondary

Measure	Time frame
skin biophysical parameters (hydration, transepidermal water loss, erythema index, melanin index)	—

Countries

Korea, Republic of

Contacts

Public ContactYeon Joo Jung

Samsung Medical Center

jyj95990@naver.com+82-2-3410-3543

Outcome results